TPO-Specific Oligonucleotide Inhibition With Safe Platelet Thresholds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments fail to safely reduce thrombopoietin (TPO) activity without significantly lowering platelet counts, which are crucial for managing diseases such as cancer, cardiovascular conditions, and autoimmune diseases.
Innovation Solution
The use of TPO-specific inhibitors, including modified oligonucleotides, to selectively decrease TPO expression or activity while maintaining platelet counts above a certain threshold, thereby inhibiting TPO-related disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If TPO inhibitors are used to reduce TPO activity, then TPO-related disease progression is inhibited, but platelet counts may drop below safe thresholds
Solution Approach 1:
The patent applies local quality by targeting TPO inhibition specifically in pathological contexts (cancer, autoimmune diseases) while preserving normal platelet production. The modified oligonucleotides are designed to bind specifically to TPO mRNA, reducing TPO activity only where pathological platelet production occurs, rather than systemically suppressing all platelet production.
Solution Approach 2:
The patent employs parameter changes by modifying the oligonucleotide structure (chemical modifications, length, sequence composition) to optimize the balance between TPO inhibition efficacy and platelet count maintenance. By adjusting these parameters, the treatment achieves sufficient TPO reduction for therapeutic effect while maintaining platelet counts above safe thresholds.
2Productivity
If conventional TPO suppression methods are used, then platelet production is reduced, but harmful side effects and excessive platelet depletion occur
Solution Approach 1:
The patent uses modified oligonucleotides as intermediaries that specifically bind to TPO mRNA to prevent its translation into TPO protein. This intermediary approach allows controlled reduction of TPO activity without the harsh side effects of conventional TPO suppression methods, as the oligonucleotides act as selective molecular mediators rather than broad-spectrum inhibitors.
Solution Approach 2:
The patent employs modified oligonucleotides that are complementary copies of specific regions of TPO mRNA. These copied sequences bind specifically to the target mRNA, enabling precise inhibition of TPO production while leaving other physiological processes unaffected, thereby reducing harmful side effects.
Data Source
AI summary
Provided herein are methods, compounds, and compositions for safely reducing thrombopoietin in a cell or an individual. Such methods, compounds, and compositions maintain platelet count within a safe hemostatic range. Such methods, compounds, and compositions are useful to safely treat, prevent, or ameliorate a disease that can benefit from platelet count reduction in an individual. Such methods, compounds, and compositions are useful for treating or preventing diseases in which thrombopoietin contributes to the presence or activation of platelets contributes to and promotes disease initiation or progression, and/or adversely affects disease outcome.